News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Samsung Biologics Raises $2 Billion In Korean IPO



11/14/2016 9:44:21 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Samsung Biologics completed a $2 billion IPO in South Korea at an $8 billion valuation. The company, a division of the large Samsung semiconductor conglomerate, has two divisions: a biologics contract manufacturer, and Bioepis, a joint venture with Biogen that makes biosimilar drugs. Samsung Biologics will use the proceeds to complete construction of its third manufacturing facility, a $740 million project, which will give it the biggest capacity of any biologic CMO and is expected to become operational in 2018.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES